Excretion of abnormally high level of CALCIUM in the URINE, greater than 4 mg/kg/day.
Disorders in the processing of calcium in the body: its absorption, transport, storage, and utilization.
A condition characterized by calcification of the renal tissue itself. It is usually seen in distal RENAL TUBULAR ACIDOSIS with calcium deposition in the DISTAL KIDNEY TUBULES and the surrounding interstitium. Nephrocalcinosis causes RENAL INSUFFICIENCY.
A non-electrogenic sodium-dependent phosphate transporter. It is found primarily in apical membranes of PROXIMAL RENAL TUBULES.
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.
Formation of stones in the KIDNEY.
A hereditary disorder characterized by HYPOPHOSPHATEMIA; RICKETS; OSTEOMALACIA; renal defects in phosphate reabsorption and vitamin D metabolism; and growth retardation. Autosomal and X-linked dominant and recessive variants have been reported.
Genetic defects in the selective or non-selective transport functions of the KIDNEY TUBULES.
Low-density crystals or stones in any part of the URINARY TRACT. Their chemical compositions often include CALCIUM OXALATE, magnesium ammonium phosphate (struvite), CYSTINE, or URIC ACID.
A large family of transmembrane proteins found in TIGHT JUNCTIONS. They take part in the formation of paracellular barriers and pores that regulate paracellular permeability.
Formation of stones in any part of the URINARY TRACT, usually in the KIDNEY; URINARY BLADDER; or the URETER.
A powder that dissolves in water, which is administered orally, and is used as a diuretic, expectorant, systemic alkalizer, and electrolyte replenisher.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
The calcium salt of oxalic acid, occurring in the urine as crystals and in certain calculi.
Abnormally high level of calcium in the blood.
A family of sodium-phosphate cotransporter proteins that also transport organic ANIONS. They are low affinity phosphate transporters.
A class of G-protein-coupled receptors that react to varying extracellular CALCIUM levels. Calcium-sensing receptors in the PARATHYROID GLANDS play an important role in the maintenance of calcium HOMEOSTASIS by regulating the release of PARATHYROID HORMONE. They differ from INTRACELLULAR CALCIUM-SENSING PROTEINS which sense intracellular calcium levels.
A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear. Deficiency of body magnesium can exist even when serum values are normal. In addition, magnesium deficiency may be organ-selective, since certain tissues become deficient before others. (Harrison's Principles of Internal Medicine, 12th ed, p1936)
Excretion of an excessive amount of OXALATES in the urine.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
Methods or procedures used to obtain samples of URINE.
An inherited condition of abnormally low serum levels of PHOSPHATES (below 1 mg/liter) which can occur in a number of genetic diseases with defective reabsorption of inorganic phosphorus by the PROXIMAL RENAL TUBULES. This leads to phosphaturia, HYPOPHOSPHATEMIA, and disturbances of cellular and organ functions such as those in X-LINKED HYPOPHOSPHATEMIC RICKETS; OSTEOMALACIA; and FANCONI SYNDROME.
A calcium-binding protein that mediates calcium HOMEOSTASIS in KIDNEYS, BRAIN, and other tissues. It is found in well-defined populations of NEURONS and is involved in CALCIUM SIGNALING and NEURONAL PLASTICITY. It is regulated in some tissues by VITAMIN D.
A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.
A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Calcium-binding proteins that are found in DISTAL KIDNEY TUBULES, INTESTINES, BRAIN, and other tissues where they bind, buffer and transport cytoplasmic calcium. Calbindins possess a variable number of EF-HAND MOTIFS which contain calcium-binding sites. Some isoforms are regulated by VITAMIN D.
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
A group of disorders caused by defective salt reabsorption in the ascending LOOP OF HENLE. It is characterized by severe salt-wasting, HYPOKALEMIA; HYPERCALCIURIA; metabolic ALKALOSIS, and hyper-reninemic HYPERALDOSTERONISM without HYPERTENSION. There are several subtypes including ones due to mutations in the renal specific SODIUM-POTASSIUM-CHLORIDE SYMPORTERS.
Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism.
Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.
A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.
A hereditary or acquired form of generalized dysfunction of the PROXIMAL KIDNEY TUBULE without primary involvement of the KIDNEY GLOMERULUS. It is usually characterized by the tubular wasting of nutrients and salts (GLUCOSE; AMINO ACIDS; PHOSPHATES; and BICARBONATES) resulting in HYPOKALEMIA; ACIDOSIS; HYPERCALCIURIA; and PROTEINURIA.
A group of genetic disorders of the KIDNEY TUBULES characterized by the accumulation of metabolically produced acids with elevated plasma chloride, hyperchloremic metabolic ACIDOSIS. Defective renal acidification of URINE (proximal tubules) or low renal acid excretion (distal tubules) can lead to complications such as HYPOKALEMIA, hypercalcinuria with NEPHROLITHIASIS and NEPHROCALCINOSIS, and RICKETS.
A calbindin protein found in many mammalian tissues, including the UTERUS, PLACENTA, BONE, PITUITARY GLAND, and KIDNEYS. In intestinal ENTEROCYTES it mediates intracellular calcium transport from apical to basolateral membranes via calcium binding at two EF-HAND MOTIFS. Expression is regulated in some tissues by VITAMIN D.
Involuntary discharge of URINE during sleep at night after expected age of completed development of urinary control.
X-linked recessive NEPHROLITHIASIS characterized by HYPERCALCIURIA; HYPOPHOSPHATEMIA; NEPHROCALCINOSIS; and PROTEINURIA. It is associated with mutations in the voltage-gated chloride channel, CLC-5 (Dent Disease I). Another group of mutations associated with this disease is in phosphatidylinositol 4,5-bisphosphate-5-phosphatase gene.
A VITAMIN D that can be regarded as a reduction product of vitamin D2.
Calcium compounds used as food supplements or in food to supply the body with calcium. Dietary calcium is needed during growth for bone development and for maintenance of skeletal integrity later in life to prevent osteoporosis.
Inorganic salts of phosphoric acid.
Agents that reduce the excretion of URINE, most notably the octapeptide VASOPRESSINS.
A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
A subgroup of TRP cation channels named after vanilloid receptor. They are very sensitive to TEMPERATURE and hot spicy food and CAPSAICIN. They have the TRP domain and ANKYRIN repeats. Selectivity for CALCIUM over SODIUM ranges from 3 to 100 fold.
A family of highly conserved and widely expressed sodium-phosphate cotransporter proteins. They are electrogenic sodium-dependent transporters of phosphate that were originally identified as retroviral receptors in HUMANS and have been described in yeast and many other organisms.
Heterocyclic compounds with SULFUR and NITROGEN in the ring. This term commonly refers to the BENZOTHIADIAZINES that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS and are used as DIURETICS.
The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition.
Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
Long convoluted tubules in the nephrons. They collect filtrate from blood passing through the KIDNEY GLOMERULUS and process this filtrate into URINE. Each renal tubule consists of a BOWMAN CAPSULE; PROXIMAL KIDNEY TUBULE; LOOP OF HENLE; DISTAL KIDNEY TUBULE; and KIDNEY COLLECTING DUCT leading to the central cavity of the kidney (KIDNEY PELVIS) that connects to the URETER.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Creatinine is a waste product that's generated from muscle metabolism, typically filtered through the kidneys and released in urine, with increased levels in blood indicating impaired kidney function.
A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
Examination of urine by chemical, physical, or microscopic means. Routine urinalysis usually includes performing chemical screening tests, determining specific gravity, observing any unusual color or odor, screening for bacteriuria, and examining the sediment microscopically.
A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
Cell membrane glycoproteins that form channels to selectively pass chloride ions. Nonselective blockers include FENAMATES; ETHACRYNIC ACID; and TAMOXIFEN.
Pathological processes of the PARATHYROID GLANDS. They usually manifest as hypersecretion or hyposecretion of PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.
Retrograde flow of urine from the URINARY BLADDER into the URETER. This is often due to incompetence of the vesicoureteral valve leading to ascending bacterial infection into the KIDNEY.
A family of symporters that facilitate sodium-dependent membrane transport of phosphate.
Metabolic bone diseases are a group of disorders that affect the bones' structure and strength, caused by disturbances in the normal metabolic processes involved in bone formation, resorption, or mineralization, including conditions like osteoporosis, osteomalacia, Paget's disease, and renal osteodystrophy.
Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.
The portion of renal tubule that begins from the enlarged segment of the ascending limb of the LOOP OF HENLE. It reenters the KIDNEY CORTEX and forms the convoluted segments of the distal tubule.
Presence of blood in the urine.
Uptake of substances through the lining of the INTESTINES.
The functional units of the kidney, consisting of the glomerulus and the attached tubule.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Bone loss due to osteoclastic activity.

SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. (1/112)

Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare disorder of autosomal recessive inheritance that was first described in a large consanguineous Bedouin kindred. HHRH is characterized by the presence of hypophosphatemia secondary to renal phosphate wasting, radiographic and/or histological evidence of rickets, limb deformities, muscle weakness, and bone pain. HHRH is distinct from other forms of hypophosphatemic rickets in that affected individuals present with hypercalciuria due to increased serum 1,25-dihydroxyvitamin D levels and increased intestinal calcium absorption. We performed a genomewide linkage scan combined with homozygosity mapping, using genomic DNA from a large consanguineous Bedouin kindred that included 10 patients who received the diagnosis of HHRH. The disease mapped to a 1.6-Mbp region on chromosome 9q34, which contains SLC34A3, the gene encoding the renal sodium-phosphate cotransporter NaP(i)-IIc. Nucleotide sequence analysis revealed a homozygous single-nucleotide deletion (c.228delC) in this candidate gene in all individuals affected by HHRH. This mutation is predicted to truncate the NaP(i)-IIc protein in the first membrane-spanning domain and thus likely results in a complete loss of function of this protein in individuals homozygous for c.228delC. In addition, compound heterozygous missense and deletion mutations were found in three additional unrelated HHRH kindreds, which supports the conclusion that this disease is caused by SLC34A3 mutations affecting both alleles. Individuals of the investigated kindreds who were heterozygous for a SLC34A3 mutation frequently showed hypercalciuria, often in association with mild hypophosphatemia and/or elevations in 1,25-dihydroxyvitamin D levels. We conclude that NaP(i)-IIc has a key role in the regulation of phosphate homeostasis.  (+info)

Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. (2/112)

Hypophosphatemia due to isolated renal phosphate wasting results from a heterogeneous group of disorders. Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is an autosomal recessive form that is characterized by reduced renal phosphate reabsorption, hypophosphatemia, and rickets. It can be distinguished from other forms of hypophosphatemia by increased serum levels of 1,25-dihydroxyvitamin D resulting in hypercalciuria. Using SNP array genotyping, we mapped the disease locus in two consanguineous families to the end of the long arm of chromosome 9. The candidate region contained a sodium-phosphate cotransporter gene, SLC34A3, which has been shown to be expressed in proximal tubulus cells. Sequencing of this gene revealed disease-associated mutations in five families, including two frameshift and one splice-site mutation. Loss of function of the SLC34A3 protein presumably results in a primary renal tubular defect and is compatible with the HHRH phenotype. We also show that the phosphaturic factor FGF23 (fibroblast growth factor 23), which is increased in X-linked hypophosphatemic rickets and carries activating mutations in autosomal dominant hypophosphatemic rickets, is at normal or low-normal serum levels in the patients with HHRH, further supporting a primary renal defect. Identification of the gene mutated in a further form of hypophosphatemia adds to the understanding of phosphate homeostasis and may help to elucidate the interaction of the proteins involved in this pathway.  (+info)

Hydrochlorothiazide in CLDN16 mutation. (3/112)

BACKGROUND: Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) caused by claudin-16 (CLDN16) mutation. However, the short-term efficacy of HCT to reduce hypercalciuria in FHHNC has not yet been demonstrated in a clinical trial. METHODS: Four male and four female patients with FHHNC and CLDN16 mutation, under long-standing HCT therapy (0.4-1.2 mg/kg, median 0.9 mg/kg, dose according to calciuria), aged 0.7-22.4 years, were included in a clinical study to investigate the effect of HCT on calciuria. The study design consisted of three periods: continued therapy for 4 weeks, HCT withdrawal for 6 weeks and restart of therapy at the same dose for 4 weeks. Calciuria and magnesiuria were assessed weekly as Ca/creat and Mg/creat ratio, every 2 weeks in 24 h urine, and serum Mg, K and kaliuria (s-Mg, s-K and K/creat) at weeks 0, 6, 10 and 14. The data of each study period were averaged and analysed by Friedman and Wilcoxon test. RESULTS: Ca/creat was significantly reduced by HCT (median before/at/after withdrawal 0.76/1.24/0.77 mol/mol creat; n = 8, P<0.05). The reduction of Ca/24 h by HCT was not statistically significant (0.13/0.19/0.13 mmol/kg x 24 h; n = 5). Serum Mg (0.51/0.64/0.56 mmol/l; n = 8, P<0.05) and Serum K (3.65/4.35/3.65 mmol/l; n = 8, P<0.05) were significantly higher during withdrawal. However, Mg/creat (0.98/0.90/0.90 mol/mol creat; n = 8), Mg/24 h (0.14/0.12/0.18 mmol/kg x 24h; n = 5) and K/creat (6.3/8.4/6.2 mol/mol creat; n = 8) remained statistically unchanged during withdrawal. CONCLUSIONS: We demonstrated that HCT is effective in reducing hypercalciuria due to CLDN16 mutation on a short-term basis. However, the efficacy of HCT to attenuate disease progression remains to be elucidated.  (+info)

High urinary calcium excretion and genetic susceptibility to hypertension and kidney stone disease. (4/112)

Increased urinary calcium excretion commonly is found in patients with hypertension and kidney stone disease (KSD). This study investigated the aggregation of hypertension and KSD in families of patients with KSD and hypercalciuria and explored whether obesity, excessive weight gain, and diabetes, commonly related conditions, also aggregate in these families. Consecutive patients with KSD, aged 18 to 50 yr, were recruited from a population-based Kidney Stone Center, and a 24-h urine sample was collected. The first-degree relatives of eligible patients (n = 333) and their spouse were interviewed by telephone to collect demographic and health information. Familial aggregation was assessed using generalized estimating equations. Multivariate-adjusted odds ratios (OR) revealed significant associations between hypercalciuria in patients and hypertension (OR 2.9; 95% confidence interval 1.4 to 6.2) and KSD (OR 1.9; 95% confidence interval 1.03 to 3.5) in first-degree relatives, specifically in siblings. No significant associations were found in parents or spouses or in patients with hyperuricosuria. Similarly, no aggregation with other conditions was observed. In an independent study of siblings of hypercalciuric patients with KSD, the adjusted mean fasting urinary calcium/creatinine ratio was significantly higher in the hypertensive siblings compared with normotensive siblings (0.60 +/- 0.32 versus 0.46 +/- 0.28 mmol/mmol; P < 0.05), and both sibling groups had significantly higher values than the unselected study participants (P < 0.001). Urinary sodium/creatinine and uric acid/creatinine ratios were not different among the groups. Although an environmental effect cannot be excluded fully, our findings suggest that the disturbance in calcium metabolism in hypertension and KSD has a genetic basis.  (+info)

WNK4 enhances TRPV5-mediated calcium transport: potential role in hypercalciuria of familial hyperkalemic hypertension caused by gene mutation of WNK4. (5/112)

The epithelial Ca(2+) channel TRPV5 serves as a gatekeeper for active Ca(2+) reabsorption in the distal convoluted tubule and connecting tubule of the kidney. WNK4, a protein serine/threonine kinase with gene mutations that cause familial hyperkalemic hypertension (FHH), including a subtype with hypercalciuria, is also localized in the distal tubule of the nephron. To understand the role of WNK4 in modulation of Ca(2+) reabsorption, we evaluated the effect of WNK4 on TRPV5-mediated Ca(2+) transport in Xenopus laevis oocytes. Coexpression of TRPV5 with WNK4 resulted in a twofold increase in TRPV5-mediated Ca(2+) uptake. The increase in Ca(2+) uptake was due to the increase in surface expression of TRPV5. When the thiazide-sensitive Na(+)-Cl(-) cotransporter NCC was coexpressed, the effect of WNK4 on TRPV5 was weakened by NCC in a dose-dependent manner. Although the WNK4 disease-causing mutants E562K, D564A, Q565E, and R1185C retained their ability to upregulate TRPV5, the blocking effect of NCC was further strengthened when wild-type WNK4 was replaced by the Q565E mutant, which causes FHH with hypercalciuria. We conclude that WNK4 positively regulates TRPV5-mediated Ca(2+) transport and that the inhibitory effect of NCC on this process may be involved in the pathogenesis of hypercalciuria of FHH caused by gene mutation in WNK4.  (+info)

Renal stone disease: Causes, evaluation and medical treatment. (6/112)

The purpose of the present review is to provide an update about the most common risk factors or medical conditions associated with renal stone formation, the current methods available for metabolic investigation, dietary recommendations and medical treatment. Laboratory investigation of hypercalciuria, hyperuricosuria, hyperoxaluria, cystinuria, hypocitraturia, renal tubular acidosis, urinary tract infection and reduction of urinary volume is based on the results of 24-hr urine collection and a spot urine for urinary sediment, culture and pH. Blood analysis for creatinine, calcium and uric acid must be obtained. Bone mineral density has to be determined mainly among hypercalciurics and primary hyperparathyroidism has to be ruled out. Current knowledge does not support calcium restriction recommendation because it can lead to secondary hyperoxaluria and bone demineralization. Reduction of animal protein and salt intake, higher fluid intake and potassium consumption should be implemented. Medical treatments involve the use of thiazides, allopurinol, potassium citrate or other drugs according to the metabolic disturbances. The correction of those metabolic abnormalities is the basic tool for prevention or reduction of recurrent stone formation.  (+info)

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. (7/112)

CONTEXT: The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated. OBJECTIVE: The objective was to examine changes in serum and urinary calcium associated with PTH(1-84) therapy in the PaTH trial and the extent to which a defined algorithm resolved the elevated values. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTION: A total of 178 postmenopausal women were randomized to PTH(1-84) either alone or in combination with alendronate during the first year of the PaTH study. MAIN OUTCOME MEASURE(S): The main outcome measures were fasting serum calcium at baseline and 1, 3, and 12 months and 24-h urinary calcium at baseline and 3 months. RESULTS: In 14% of participants, serum calcium more than 10.5 mg/dl (>2.6 mmol/liter) developed. Following the defined algorithm, 58% of elevated measurements were normal on repeat testing; 38% required discontinuation of calcium and vitamin D supplementation, and one necessitated a decrease in PTH injection frequency to normalize serum calcium. One participant developed transient hypercalcemia between study visits and required hospitalization; the episode resolved with iv hydration and PTH discontinuation. Baseline characteristics associated with the development of hypercalcemia were serum calcium [relative hazards = 1.9 per 0.5 mg/dl (0.12 mmol/liter); 95% confidence interval = 1.1-3.2] and serum 1,25-dihydroxyvitamin D [relative hazard = 1.9 per 10 pg/ml (26 pmol/liter); 95% confidence interval = 1.2-3.1]. Fifteen women (8%) developed hypercalciuria [urinary calcium > 400 mg (100 mmol)/24 h or calcium/creatinine ratio > 0.4]; 80% of cases resolved after discontinuing calcium and vitamin D, 13% without intervention, and one after PTH injection frequency was decreased. Higher baseline urinary calcium excretion was associated with development of hypercalciuria [relative hazard = 1.5 per 50 mg/d (12.5 mmol/d); 95% confidence interval = 1.2-4.0]. Proportions of patients with elevated serum and urinary calcium were similar on single and combination therapy. CONCLUSIONS: The frequency of episodic hypercalcemia or hypercalciuria in the PaTH trial was 21%. Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on PTH.  (+info)

Incomplete distal renal tubular acidosis affects growth in children. (8/112)

BACKGROUND: Incomplete distal renal tubular acidosis (idRTA) is recognized as an underlying aetiology in recurrent nephrolithiasis. Until the recently reported high prevalence of idRTA in adults with osteoporosis, the effect of idRTA on skeletal parameters was not known. We hypothesize that idRTA has a potential to affect height in the paediatric population. METHODS: In a cross-sectional study, the children with posterior urethral valves (PUV), with normal estimated glomerular filtration rates, were evaluated for idRTA and complete dRTA. The idRTA evaluation was done by short ammonium chloride acidification test. The height standard deviation scores (SDS) in the idRTA group were compared with PUV children without dRTA, with complete dRTA, and to age and gender matched controls with no renal issue (n = 50). RESULTS: The idRTA group (n = 17) manifested a significantly lower mean height SDS (-1.94 +/- 0.41 vs -0.46 +/- 0.28; P < 0.001) and a higher short stature prevalence (height SDS below 2) (18% vs 0; P = 0.06) as compared with those without dRTA (n = 23). The matched controls showed a significantly higher height SDS as compared with the idRTA group (-0.39 +/- 0.25 vs -1.94 +/- 0.41; P < 0.001). As compared with the complete dRTA group (n = 9), the children with idRTA did have significantly higher height SDS (-1.94 +/- 0.41 vs -5.31 +/- 1.95; P = 0.002), and a lower short stature prevalence (18% vs 78%; P = 0.001). On multivariate analysis, dRTA was significantly associated with the height SDS (= -0.88; P < 0.001). CONCLUSIONS: Incomplete dRTA affects height in children. This observation needs validation in longitudinal studies.  (+info)

Hypercalciuria is a medical condition characterized by an excessive amount of calcium in the urine. It can occur when the body absorbs too much calcium from food, or when the bones release more calcium than usual. In some cases, it may be caused by certain medications, kidney disorders, or genetic factors.

Hypercalciuria can increase the risk of developing kidney stones and other kidney problems. It is often diagnosed through a 24-hour urine collection test that measures the amount of calcium in the urine. Treatment may include changes in diet, increased fluid intake, and medications to help reduce the amount of calcium in the urine.

Calcium metabolism disorders refer to a group of medical conditions that affect the body's ability to properly regulate the levels of calcium in the blood and tissues. Calcium is an essential mineral that plays a critical role in many bodily functions, including bone health, muscle contraction, nerve function, and blood clotting.

There are several types of calcium metabolism disorders, including:

1. Hypocalcemia: This is a condition characterized by low levels of calcium in the blood. It can be caused by various factors such as vitamin D deficiency, hypoparathyroidism, and certain medications. Symptoms may include muscle cramps, spasms, and tingling sensations in the fingers and toes.
2. Hypercalcemia: This is a condition characterized by high levels of calcium in the blood. It can be caused by various factors such as hyperparathyroidism, cancer, and certain medications. Symptoms may include fatigue, weakness, confusion, and kidney stones.
3. Osteoporosis: This is a condition characterized by weak and brittle bones due to low calcium levels in the bones. It can be caused by various factors such as aging, menopause, vitamin D deficiency, and certain medications. Symptoms may include bone fractures and loss of height.
4. Paget's disease: This is a condition characterized by abnormal bone growth and deformities due to disordered calcium metabolism. It can be caused by various factors such as genetics, age, and certain medications. Symptoms may include bone pain, fractures, and deformities.

Treatment for calcium metabolism disorders depends on the underlying cause of the condition. It may involve supplements, medication, dietary changes, or surgery. Proper diagnosis and management are essential to prevent complications such as kidney stones, bone fractures, and neurological damage.

Nephrocalcinosis is a medical condition characterized by the deposition of calcium salts in the renal parenchyma, specifically within the tubular epithelial cells and interstitium of the kidneys. This process can lead to chronic inflammation, tissue damage, and ultimately impaired renal function if left untreated.

The condition is often associated with metabolic disorders such as hyperparathyroidism, distal renal tubular acidosis, or hyperoxaluria; medications like loop diuretics, corticosteroids, or calcineurin inhibitors; and chronic kidney diseases. The diagnosis of nephrocalcinosis is typically made through imaging studies such as ultrasound, CT scan, or X-ray. Treatment usually involves addressing the underlying cause, modifying dietary habits, and administering medications to control calcium levels in the body.

Sodium-phosphate cotransporter proteins, type IIc (NPTIIc), are a subtype of sodium-dependent phosphate transporters that play a crucial role in the regulation of phosphate homeostasis within the body. They are located primarily in the kidney's proximal tubule cells and intestinal epithelial cells.

NPTIIc proteins facilitate the active transport of inorganic phosphate (Pi) ions across the cell membrane, in conjunction with sodium ions (Na+). This symport mechanism allows for the movement of Pi against its concentration gradient, from areas of low concentration to high concentration. The energy required for this process is derived from the electrochemical gradient of sodium ions.

These transporters are essential for maintaining normal phosphate levels in the body, as they help reabsorb a significant portion of filtered phosphate in the kidneys and absorb dietary phosphate in the intestines. Dysregulation of NPTIIc proteins can lead to various disorders related to phosphate homeostasis, such as hypophosphatemia (low serum phosphate levels) or hyperphosphatemia (high serum phosphate levels), which can have detrimental effects on bone health, mineral metabolism, and overall body function.

Kidney calculi, also known as kidney stones, are hard deposits made of minerals and salts that form inside your kidneys. They can range in size from a grain of sand to a golf ball. When they're small enough, they can be passed through your urine without causing too much discomfort. However, larger stones may block the flow of urine, causing severe pain and potentially leading to serious complications such as urinary tract infections or kidney damage if left untreated.

The formation of kidney calculi is often associated with factors like dehydration, high levels of certain minerals in your urine, family history, obesity, and certain medical conditions such as gout or inflammatory bowel disease. Symptoms of kidney stones typically include severe pain in the back, side, lower abdomen, or groin; nausea and vomiting; fever and chills if an infection is present; and blood in the urine. Treatment options depend on the size and location of the stone but may include medications to help pass the stone, shock wave lithotripsy to break up the stone, or surgical removal of the stone in severe cases.

Nephrolithiasis is a medical term that refers to the presence of stones or calculi in the kidney. These stones can form anywhere in the urinary tract, including the kidneys, ureters, bladder, and urethra. Nephrolithiasis is also commonly known as kidney stones.

Kidney stones are hard deposits made up of minerals and salts that crystallize in the urine. They can vary in size from tiny sand-like particles to larger pebble or even golf ball-sized masses. Kidney stones can cause pain, bleeding, and infection if they block the flow of urine through the urinary tract.

The formation of kidney stones is often associated with a variety of factors such as dehydration, high levels of calcium, oxalate, or uric acid in the urine, family history, obesity, and certain medical conditions like gout or inflammatory bowel disease. Treatment for nephrolithiasis depends on the size and location of the stone, as well as the severity of symptoms. Small stones may pass spontaneously with increased fluid intake, while larger stones may require medication, shock wave lithotripsy, or surgical removal.

Familial Hypophosphatemic Rickets (FHR) is a genetic disorder characterized by impaired reabsorption of phosphate in the kidneys, leading to low levels of phosphate in the blood (hypophosphatemia). This condition results in defective mineralization of bones and teeth, causing rickets in children and osteomalacia in adults.

FHR is typically caused by mutations in the PHEX gene, which encodes a protein that helps regulate phosphate levels in the body. In FHR, the mutation leads to an overproduction of a hormone called fibroblast growth factor 23 (FGF23), which increases phosphate excretion in the urine and decreases the activation of vitamin D, further contributing to hypophosphatemia.

Symptoms of FHR may include bowing of the legs, bone pain, muscle weakness, short stature, dental abnormalities, and skeletal deformities. Treatment typically involves oral phosphate supplements and active forms of vitamin D to correct the hypophosphatemia and improve bone mineralization. Regular monitoring of blood phosphate levels, kidney function, and bone health is essential for effective management of this condition.

Inborn errors of renal tubular transport refer to genetic disorders that affect the normal functioning of the kidney tubules. The kidney tubules are responsible for the reabsorption and secretion of various substances, including electrolytes and nutrients, as urine is formed. Inherited defects in the proteins that mediate these transport processes can lead to abnormal levels of these substances in the body and may result in a variety of clinical symptoms.

These disorders can affect different parts of the renal tubule, including the proximal tubule, loop of Henle, distal tubule, and collecting duct. Depending on the specific transporter affected, inborn errors of renal tubular transport can present with a range of clinical manifestations, such as electrolyte imbalances, acid-base disorders, growth retardation, kidney stones, nephrocalcinosis, or even kidney failure.

Examples of inborn errors of renal tubular transport include:

1. Distal renal tubular acidosis (dRTA): A genetic disorder that affects the ability of the distal tubule to acidify urine, leading to metabolic acidosis, hypokalemia, and nephrocalcinosis.
2. Bartter syndrome: A group of autosomal recessive disorders characterized by impaired sodium reabsorption in the loop of Henle, resulting in hypokalemia, metabolic alkalosis, and hyperreninemic hyperaldosteronism.
3. Gitelman syndrome: An autosomal recessive disorder caused by a defect in the thiazide-sensitive sodium chloride cotransporter in the distal tubule, leading to hypokalemia, metabolic alkalosis, and hypocalciuria.
4. Liddle syndrome: An autosomal dominant disorder characterized by increased sodium reabsorption in the collecting duct due to a gain-of-function mutation in the epithelial sodium channel (ENaC), resulting in hypertension, hypokalemia, and metabolic alkalosis.
5. Dent disease: An X-linked recessive disorder caused by mutations in the CLCN5 gene, which encodes a chloride channel in the proximal tubule, leading to low molecular weight proteinuria, hypercalciuria, and nephrolithiasis.
6. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC): An autosomal recessive disorder caused by mutations in the CLCN5 or CLDN16 genes, which encode chloride channels in the thick ascending limb of Henle's loop, resulting in hypomagnesemia, hypercalciuria, and nephrocalcinosis.

Urinary calculi, also known as kidney stones or nephrolithiasis, are hard deposits made of minerals and salts that form inside the urinary system. These calculi can develop in any part of the urinary system, which includes the kidneys, ureters, bladder, and urethra.

The formation of urinary calculi typically occurs when there is a concentration of certain substances, such as calcium, oxalate, uric acid, or struvite, in the urine. When these substances become highly concentrated, they can crystallize and form small seeds that gradually grow into larger stones over time.

The size of urinary calculi can vary from tiny, sand-like particles to large stones that can fill the entire renal pelvis. The symptoms associated with urinary calculi depend on the stone's size, location, and whether it is causing a blockage in the urinary tract. Common symptoms include severe pain in the flank, lower abdomen, or groin; nausea and vomiting; blood in the urine (hematuria); fever and chills; and frequent urge to urinate or painful urination.

Treatment for urinary calculi depends on the size and location of the stone, as well as the severity of symptoms. Small stones may pass spontaneously with increased fluid intake and pain management. Larger stones may require medical intervention, such as extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, or percutaneous nephrolithotomy (PCNL) to break up or remove the stone. Preventive measures include maintaining adequate hydration, modifying dietary habits, and taking medications to reduce the risk of stone formation.

Claudins are a group of proteins that play a crucial role in the formation and function of tight junctions, which are specialized structures found in the cell membranes of epithelial and endothelial cells. Tight junctions serve as barriers to regulate the paracellular movement of ions, solutes, and water between cells, and claudins are one of the major components that contribute to their selective permeability.

There are over 20 different types of claudins identified in various tissues throughout the body, with each type having a unique structure and function. Claudins can form homotypic or heterotypic interactions with other claudin molecules, allowing for the formation of tight junction strands with varying pore sizes and charge selectivity. This diversity in claudin composition enables the regulation of paracellular transport across different tissues, such as the blood-brain barrier, intestinal epithelium, and renal tubules.

Mutations or dysregulation of claudins have been implicated in several diseases, including cancer, inflammatory bowel disease, and neurological disorders. For example, altered expression levels of specific claudins can contribute to the development of drug resistance in certain types of cancer cells, making them more difficult to treat. Additionally, changes in claudin composition or distribution can disrupt tight junction function, leading to increased permeability and the onset of various pathological conditions.

Urolithiasis is the formation of stones (calculi) in the urinary system, which includes the kidneys, ureters, bladder, and urethra. These stones can be composed of various substances such as calcium oxalate, calcium phosphate, uric acid, or struvite. The presence of urolithiasis can cause symptoms like severe pain in the back or side, nausea, vomiting, fever, and blood in the urine. The condition can be managed with medications, increased fluid intake, and in some cases, surgical intervention may be required to remove the stones.

Potassium citrate is a medication and dietary supplement that contains potassium and citrate. Medically, it is used to treat and prevent kidney stones, as well as to manage metabolic acidosis in people with chronic kidney disease. Potassium citrate works by increasing the pH of urine, making it less acidic, which can help to dissolve certain types of kidney stones and prevent new ones from forming. It is also used as an alkalizing agent in the treatment of various conditions that cause acidosis.

In addition to its medical uses, potassium citrate is also found naturally in some fruits and vegetables, such as oranges, grapefruits, lemons, limes, and spinach. It is often used as a food additive and preservative, and can be found in a variety of processed foods and beverages.

It's important to note that taking too much potassium citrate can lead to high levels of potassium in the blood, which can be dangerous. Therefore, it is important to follow the dosage instructions carefully and talk to your doctor before taking this medication if you have any medical conditions or are taking any other medications.

Calcium is an essential mineral that is vital for various physiological processes in the human body. The medical definition of calcium is as follows:

Calcium (Ca2+) is a crucial cation and the most abundant mineral in the human body, with approximately 99% of it found in bones and teeth. It plays a vital role in maintaining structural integrity, nerve impulse transmission, muscle contraction, hormonal secretion, blood coagulation, and enzyme activation.

Calcium homeostasis is tightly regulated through the interplay of several hormones, including parathyroid hormone (PTH), calcitonin, and vitamin D. Dietary calcium intake, absorption, and excretion are also critical factors in maintaining optimal calcium levels in the body.

Hypocalcemia refers to low serum calcium levels, while hypercalcemia indicates high serum calcium levels. Both conditions can have detrimental effects on various organ systems and require medical intervention to correct.

Calcium oxalate is a chemical compound with the formula CaC2O4. It is the most common type of stone found in kidneys, also known as kidney stones. Calcium oxalate forms when there is too much calcium or oxalate in the urine. This can occur due to various reasons such as dietary habits, dehydration, medical conditions like hyperparathyroidism, or genetic factors.

Calcium oxalate stones are hard and crystalline and can cause severe pain during urination or while passing through the urinary tract. They may also lead to other symptoms like blood in the urine, nausea, vomiting, or fever. Prevention strategies for calcium oxalate stones include staying hydrated, following a balanced diet, and taking prescribed medications to control the levels of calcium and oxalate in the body.

Hypercalcemia is a medical condition characterized by an excess of calcium ( Ca2+ ) in the blood. While the normal range for serum calcium levels is typically between 8.5 to 10.2 mg/dL (milligrams per deciliter) or 2.14 to 2.55 mmol/L (millimoles per liter), hypercalcemia is generally defined as a serum calcium level greater than 10.5 mg/dL or 2.6 mmol/L.

Hypercalcemia can result from various underlying medical disorders, including primary hyperparathyroidism, malignancy (cancer), certain medications, granulomatous diseases, and excessive vitamin D intake or production. Symptoms of hypercalcemia may include fatigue, weakness, confusion, memory loss, depression, constipation, nausea, vomiting, increased thirst, frequent urination, bone pain, and kidney stones. Severe or prolonged hypercalcemia can lead to serious complications such as kidney failure, cardiac arrhythmias, and calcification of soft tissues. Treatment depends on the underlying cause and severity of the condition.

Sodium-phosphate cotransporter proteins, type I (NaPi-I), are a group of membrane transport proteins that facilitate the active transport of sodium and phosphate ions across the cell membrane. These proteins play a crucial role in regulating phosphate homeostasis in the body by reabsorbing phosphate from the glomerular filtrate in the kidney back into the bloodstream.

The type I sodium-phosphate cotransporters are composed of two subtypes, NaPi-IA and NaPi-IB, which share a similar structure and function. They consist of 13 transmembrane domains, with both the N- and C-termini located in the cytoplasm. These proteins are primarily expressed in the brush border membrane of the proximal tubule cells in the kidney.

NaPi-I proteins function as sodium-phosphate symporters, meaning they transport both sodium and phosphate ions in the same direction. The energy required for this active transport process comes from the electrochemical gradient of sodium ions across the cell membrane, which is maintained by the activity of the Na+/K+-ATPase pump.

Regulation of these proteins is critical for maintaining phosphate balance in the body. In response to changes in dietary phosphate intake or hormonal signals, such as parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), the expression and activity of NaPi-I proteins can be modulated to adjust phosphate reabsorption in the kidney.

In summary, sodium-phosphate cotransporter proteins, type I, are essential membrane transport proteins that regulate phosphate homeostasis by facilitating the active reabsorption of phosphate from the glomerular filtrate in the kidney. Their expression and activity are tightly regulated to maintain proper phosphate balance in the body.

Calcium-sensing receptors (CaSR) are a type of G protein-coupled receptor that play a crucial role in the regulation of extracellular calcium homeostasis. They are widely expressed in various tissues, including the parathyroid gland, kidney, and bone.

The primary function of CaSR is to detect changes in extracellular calcium concentrations and transmit signals to regulate the release of parathyroid hormone (PTH) from the parathyroid gland. When the concentration of extracellular calcium increases, CaSR is activated, which leads to a decrease in PTH secretion, thereby preventing further elevation of calcium levels. Conversely, when calcium levels decrease, CaSR is inhibited, leading to an increase in PTH release and restoration of normal calcium levels.

In addition to regulating calcium homeostasis, CaSR also plays a role in other physiological processes, including cell proliferation, differentiation, and apoptosis. Dysregulation of CaSR has been implicated in various diseases, such as hyperparathyroidism, hypoparathyroidism, and cancer. Therefore, understanding the function and regulation of CaSR is essential for developing new therapeutic strategies to treat these conditions.

Magnesium deficiency, also known as hypomagnesemia, is a condition characterized by low levels of magnesium in the blood. Magnesium is an essential mineral that plays a crucial role in many bodily functions, including muscle and nerve function, heart rhythm, bone strength, and immune system regulation.

Hypomagnesemia can occur due to various factors, such as poor dietary intake, malabsorption syndromes, chronic alcoholism, diabetes, certain medications (such as diuretics), and excessive sweating or urination. Symptoms of magnesium deficiency may include muscle cramps, tremors, weakness, heart rhythm abnormalities, seizures, and mental status changes.

It is important to note that mild magnesium deficiency may not cause any symptoms, and the diagnosis typically requires blood tests to measure magnesium levels. Treatment for hypomagnesemia usually involves oral or intravenous magnesium supplementation, along with addressing the underlying causes of the deficiency.

Hyperoxaluria is a medical condition characterized by an excessive excretion of oxalate in the urine. Oxalate is a naturally occurring substance found in some foods and can also be produced by the body. When oxalate combines with calcium in the urine, it can form kidney stones or calcium oxalate deposits in the kidneys and other tissues, leading to kidney damage or systemic oxalosis. There are three types of hyperoxaluria: primary, secondary, and enteric. Primary hyperoxaluria is caused by genetic defects that affect the body's ability to regulate oxalate production, while secondary hyperoxaluria results from increased dietary intake or absorption of oxalate, or from other medical conditions. Enteric hyperoxaluria occurs in individuals with malabsorption syndromes, such as inflammatory bowel disease or after gastric bypass surgery, where excessive amounts of oxalate are absorbed from the gut into the bloodstream and excreted in the urine.

Parathyroid hormone (PTH) is a polypeptide hormone that plays a crucial role in the regulation of calcium and phosphate levels in the body. It is produced and secreted by the parathyroid glands, which are four small endocrine glands located on the back surface of the thyroid gland.

The primary function of PTH is to maintain normal calcium levels in the blood by increasing calcium absorption from the gut, mobilizing calcium from bones, and decreasing calcium excretion by the kidneys. PTH also increases phosphate excretion by the kidneys, which helps to lower serum phosphate levels.

In addition to its role in calcium and phosphate homeostasis, PTH has been shown to have anabolic effects on bone tissue, stimulating bone formation and preventing bone loss. However, chronic elevations in PTH levels can lead to excessive bone resorption and osteoporosis.

Overall, Parathyroid Hormone is a critical hormone that helps maintain mineral homeostasis and supports healthy bone metabolism.

Urine specimen collection is the process of obtaining a urine sample from a person for laboratory testing and analysis. This procedure is used to diagnose and monitor various medical conditions, such as urinary tract infections, kidney diseases, diabetes, and other metabolic disorders. The collection process should be performed using sterile techniques to avoid contamination and ensure accurate test results.

There are different methods for collecting urine specimens, including:

1. Clean-catch midstream collection: This is the most common method used for routine urinalysis. The individual is asked to clean the genital area with a cleansing wipe, start urinating, and then collect a small amount of the middle portion of the urine stream in a sterile container.
2. Catheterization: In cases where the individual cannot voluntarily urinate, or when a sterile sample is required, a healthcare professional may insert a sterile catheter into the bladder to drain the urine directly into a sterile container.
3. Suprapubic aspiration: This method is rarely used and involves inserting a needle through the abdominal wall and into the bladder to collect urine with a syringe. It is typically reserved for infants or individuals who cannot undergo catheterization.
4. 24-hour urine collection: For specific tests that require measuring the total amount of certain substances excreted in urine over a 24-hour period, the individual collects all urine passed during this time frame in a special container with a preservative.

Proper handling and storage of the collected urine specimen are essential to maintain the integrity of the sample and ensure accurate test results.

Familial Hypophosphatemia is a genetic disorder characterized by low levels of phosphate in the blood (hypophosphatemia) due to impaired absorption of phosphates in the gut. This condition results from mutations in the SLC34A3 gene, which provides instructions for making a protein called NaPi-IIc, responsible for reabsorbing phosphates from the filtrate in the kidney tubules back into the bloodstream.

In familial hypophosphatemia, the impaired function of NaPi-IIc leads to excessive loss of phosphate through urine, resulting in hypophosphatemia. This condition can cause rickets (a softening and weakening of bones) in children and osteomalacia (softening of bones) in adults. Symptoms may include bowed legs, bone pain, muscle weakness, and short stature.

Familial Hypophosphatemia is inherited as an autosomal recessive trait, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition.

Calbindin 1 is a calcium-binding protein that belongs to the family of EF-hand proteins. It is also known as calbindin D-28k, due to its molecular weight of approximately 28 kilodaltons. This protein is widely distributed in various tissues and organisms but is particularly abundant in the nervous system, where it plays crucial roles in calcium homeostasis, neuroprotection, and signal transduction.

In neurons, calbindin 1 is primarily located in the cytoplasm and dendrites, with lower concentrations found in the axons and nerve terminals. It helps regulate intracellular calcium levels by binding to calcium ions (Ca2+) with high affinity and capacity, thereby preventing rapid fluctuations in Ca2+ concentration that could trigger cellular damage or dysfunction.

Calbindin 1 has been implicated in several neuronal processes, including neurotransmitter release, synaptic plasticity, and neuronal excitability. Additionally, it is believed to provide neuroprotection against various insults, such as oxidative stress, glutamate excitotoxicity, and calcium overload, which are associated with neurological disorders like Alzheimer's disease, Parkinson's disease, and epilepsy.

In summary, calbindin 1 is a calcium-binding protein that plays essential roles in maintaining calcium homeostasis, neuroprotection, and neuronal signaling within the nervous system.

Phosphorus is an essential mineral that is required by every cell in the body for normal functioning. It is a key component of several important biomolecules, including adenosine triphosphate (ATP), which is the primary source of energy for cells, and deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which are the genetic materials in cells.

Phosphorus is also a major constituent of bones and teeth, where it combines with calcium to provide strength and structure. In addition, phosphorus plays a critical role in various metabolic processes, including energy production, nerve impulse transmission, and pH regulation.

The medical definition of phosphorus refers to the chemical element with the atomic number 15 and the symbol P. It is a highly reactive non-metal that exists in several forms, including white phosphorus, red phosphorus, and black phosphorus. In the body, phosphorus is primarily found in the form of organic compounds, such as phospholipids, phosphoproteins, and nucleic acids.

Abnormal levels of phosphorus in the body can lead to various health problems. For example, high levels of phosphorus (hyperphosphatemia) can occur in patients with kidney disease or those who consume large amounts of phosphorus-rich foods, and can contribute to the development of calcification of soft tissues and cardiovascular disease. On the other hand, low levels of phosphorus (hypophosphatemia) can occur in patients with malnutrition, vitamin D deficiency, or alcoholism, and can lead to muscle weakness, bone pain, and an increased risk of infection.

Chlorothiazide is a medication that belongs to a class of diuretics known as thiazide diuretics. It works by increasing the excretion of salt and water from the body through urine, which helps to reduce blood pressure and decrease edema (swelling). Chlorothiazide is used to treat hypertension (high blood pressure), heart failure, and edema caused by various medical conditions.

The medical definition of Chlorothiazide is:

A thiazide diuretic drug used in the treatment of hypertension, heart failure, and edema. It acts by inhibiting the reabsorption of sodium and chloride ions in the distal convoluted tubule of the nephron, leading to increased excretion of salt and water in the urine. Chlorothiazide has a rapid onset of action and a short duration of effect, making it useful for acute situations requiring prompt diuresis. It is available in oral and injectable forms.

Calbindins are a family of calcium-binding proteins that are widely distributed in various tissues, including the gastrointestinal tract, brain, and kidney. They play important roles in regulating intracellular calcium levels and modulating calcium-dependent signaling pathways. Calbindin D28k, one of the major isoforms, is particularly abundant in the central nervous system and has been implicated in neuroprotection, neuronal plasticity, and regulation of neurotransmitter release. Deficiencies or alterations in calbindins have been associated with various pathological conditions, including neurological disorders and cancer.

Calcitriol is the active form of vitamin D, also known as 1,25-dihydroxyvitamin D. It is a steroid hormone that plays a crucial role in regulating calcium and phosphate levels in the body to maintain healthy bones. Calcitriol is produced in the kidneys from its precursor, calcidiol (25-hydroxyvitamin D), which is derived from dietary sources or synthesized in the skin upon exposure to sunlight.

Calcitriol promotes calcium absorption in the intestines, helps regulate calcium and phosphate levels in the kidneys, and stimulates bone cells (osteoblasts) to form new bone tissue while inhibiting the activity of osteoclasts, which resorb bone. This hormone is essential for normal bone mineralization and growth, as well as for preventing hypocalcemia (low calcium levels).

In addition to its role in bone health, calcitriol has various other physiological functions, including modulating immune responses, cell proliferation, differentiation, and apoptosis. Calcitriol deficiency or resistance can lead to conditions such as rickets in children and osteomalacia or osteoporosis in adults.

Trichlormethiazide is a thiazide diuretic drug, which is primarily used to treat hypertension (high blood pressure) and edema (fluid retention) associated with various medical conditions such as heart failure, kidney disease, or liver cirrhosis. It works by increasing the excretion of salt and water from the body through urine, thereby reducing fluid volume and lowering blood pressure.

The medical definition of Trichlormethiazide is:

A potent long-acting oral thiazide diuretic with a chlorothiazide side chain at position 2 and trichloromethyl group at position 6 of the benzothiadiazine ring. It has a longer duration of action than other thiazides, making it suitable for once-daily dosing in the management of hypertension and edema. Its diuretic effect is mainly due to inhibition of sodium reabsorption in the distal convoluted tubule of the kidney, leading to increased excretion of water and electrolytes (particularly sodium and chloride ions) in the urine.

Trichlormethiazide is available under various brand names, such as Metahydrin, Naqua, and Diuril Sodium. It should be used with caution and under medical supervision due to potential side effects like electrolyte imbalance, dehydration, hypotension, and impaired glucose tolerance.

Bartter syndrome is a rare genetic disorder that affects the kidneys' ability to reabsorb sodium and chloride, leading to an imbalance of electrolytes in the body. This condition is characterized by hypokalemia (low potassium levels), metabolic alkalosis (high pH levels in the blood), and normal or low blood pressure. It can also result in increased urine production, excessive thirst, and growth retardation in children. There are two major types of Bartter syndrome, based on the genes affected: type I caused by mutations in the SLC12A1 gene, and type II caused by mutations in the KCNJ1 gene. Type III is caused by mutations in the CLCNKB gene, while type IV is caused by mutations in the BSND or CLCNKB genes. Treatment typically involves supplementation of electrolytes, such as potassium and magnesium, as well as nonsteroidal anti-inflammatory drugs (NSAIDs) to help reduce sodium loss in the urine.

14-alpha Demethylase Inhibitors are a class of antifungal medications that work by inhibiting the enzyme 14-alpha demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. By inhibiting this enzyme, the drugs disrupt the structure and function of the fungal cell membrane, leading to fungal cell death.

Examples of 14-alpha Demethylase Inhibitors include:

* Fluconazole (Diflucan)
* Itraconazole (Sporanox)
* Ketoconazole (Nizoral)
* Posaconazole (Noxafil)
* Voriconazole (Vfend)

These medications are used to treat a variety of fungal infections, including candidiasis, aspergillosis, and cryptococcosis. However, they can also have significant drug-drug interactions and toxicities, so their use must be monitored closely by healthcare professionals.

Oxalates, also known as oxalic acid or oxalate salts, are organic compounds that contain the functional group called oxalate. Oxalates are naturally occurring substances found in various foods such as spinach, rhubarb, nuts, and seeds. They can also be produced by the body as a result of metabolism.

In the body, oxalates can bind with calcium and other minerals to form crystals, which can accumulate in various tissues and organs, including the kidneys. This can lead to the formation of kidney stones, which are a common health problem associated with high oxalate intake or increased oxalate production in the body.

It is important for individuals with a history of kidney stones or other kidney problems to monitor their oxalate intake and limit consumption of high-oxalate foods. Additionally, certain medical conditions such as hyperoxaluria, a rare genetic disorder that causes increased oxalate production in the body, may require medical treatment to reduce oxalate levels and prevent complications.

Hypoparathyroidism is a medical condition characterized by decreased levels or insufficient function of parathyroid hormone (PTH), which is produced and released by the parathyroid glands. These glands are located in the neck, near the thyroid gland, and play a crucial role in regulating calcium and phosphorus levels in the body.

In hypoparathyroidism, low PTH levels result in decreased absorption of calcium from the gut, increased excretion of calcium through the kidneys, and impaired regulation of bone metabolism. This leads to low serum calcium levels (hypocalcemia) and high serum phosphorus levels (hyperphosphatemia).

Symptoms of hypoparathyroidism can include muscle cramps, spasms, or tetany (involuntary muscle contractions), numbness or tingling sensations in the fingers, toes, and around the mouth, fatigue, weakness, anxiety, cognitive impairment, and in severe cases, seizures. Hypoparathyroidism can be caused by various factors, including surgical removal or damage to the parathyroid glands, autoimmune disorders, radiation therapy, genetic defects, or low magnesium levels. Treatment typically involves calcium and vitamin D supplementation to maintain normal serum calcium levels and alleviate symptoms. In some cases, recombinant PTH (Natpara) may be prescribed as well.

Fanconi syndrome is a medical condition that affects the proximal tubules of the kidneys. These tubules are responsible for reabsorbing various substances, such as glucose, amino acids, and electrolytes, back into the bloodstream after they have been filtered through the kidneys.

In Fanconi syndrome, there is a defect in the reabsorption process, causing these substances to be lost in the urine instead. This can lead to a variety of symptoms, including:

* Polyuria (excessive urination)
* Polydipsia (excessive thirst)
* Dehydration
* Metabolic acidosis (an imbalance of acid and base in the body)
* Hypokalemia (low potassium levels)
* Hypophosphatemia (low phosphate levels)
* Vitamin D deficiency
* Rickets (softening and weakening of bones in children) or osteomalacia (softening of bones in adults)

Fanconi syndrome can be caused by a variety of underlying conditions, including genetic disorders, kidney diseases, drug toxicity, and heavy metal poisoning. Treatment typically involves addressing the underlying cause, as well as managing symptoms such as electrolyte imbalances and acid-base disturbances.

Renal tubular acidosis (RTA) is a medical condition that occurs when the kidneys are unable to properly excrete acid into the urine, leading to an accumulation of acid in the bloodstream. This results in a state of metabolic acidosis.

There are several types of RTA, but renal tubular acidosis type 1 (also known as distal RTA) is characterized by a defect in the ability of the distal tubules to acidify the urine, leading to an inability to lower the pH of the urine below 5.5, even in the face of metabolic acidosis. This results in a persistently alkaline urine, which can lead to calcium phosphate stones and bone demineralization.

Type 1 RTA is often caused by inherited genetic defects, but it can also be acquired due to various kidney diseases, drugs, or autoimmune disorders. Symptoms of type 1 RTA may include fatigue, weakness, muscle cramps, decreased appetite, and vomiting. Treatment typically involves alkali therapy to correct the acidosis and prevent complications.

S100 calcium binding protein G, also known as calgranulin A or S100A8, is a member of the S100 family of proteins. These proteins are characterized by their ability to bind calcium ions and play a role in intracellular signaling and regulation of various cellular processes.

S100 calcium binding protein G forms a heterodimer with S100 calcium binding protein B (S100A9) and is involved in the inflammatory response, immune function, and tumor growth and progression. The S100A8/A9 heterocomplex has been shown to play a role in neutrophil activation and recruitment, as well as the regulation of cytokine production and cell proliferation.

Elevated levels of S100 calcium binding protein G have been found in various inflammatory conditions, such as rheumatoid arthritis, Crohn's disease, and psoriasis, as well as in several types of cancer, including breast, lung, and colon cancer. Therefore, it has been suggested that S100 calcium binding protein G may be a useful biomarker for the diagnosis and prognosis of these conditions.

Nocturnal enuresis, also known as bedwetting, is a medical condition where an individual, usually a child, urinates involuntarily during sleep. It is considered to be a disorder when it occurs in children over the age of 5 years old, and is more common in boys than girls. Nocturnal enuresis can have various causes, including delayed development of bladder control, small bladder capacity, sleep disorders, urinary tract infections, structural or neurological abnormalities, and family history. Treatment options may include behavioral interventions, such as bladder training and fluid restriction, medications, or a combination of both.

Dent disease is a rare X-linked recessive genetic disorder that primarily affects the function of the proximal tubules in the kidneys. It is characterized by low molecular weight proteinuria, hypercalciuria, nephrolithiasis (kidney stones), and progressive kidney dysfunction leading to chronic kidney disease or end-stage renal failure in some cases. The disorder is caused by mutations in the CLCN5 gene, which provides instructions for making a chloride channel important for maintaining the proper function of proximal tubular cells in the kidneys. Dent disease primarily affects males, while females are typically asymptomatic carriers of the disorder.

Dihydrotachysterol is a synthetic form of vitamin D that is used as a medication to treat hypocalcemia (low levels of calcium in the blood) in people with certain medical conditions, such as hypoparathyroidism and vitamin D deficiency. It works by increasing the absorption of calcium from the gut and promoting the release of calcium from bones into the bloodstream.

Dihydrotachysterol is available in tablet form and is typically taken once or twice a day, with the dosage adjusted based on the individual's response to treatment and serum calcium levels. Common side effects of dihydrotachysterol include hypercalcemia (high levels of calcium in the blood), nausea, vomiting, and constipation. It is important to monitor serum calcium levels regularly while taking this medication to prevent toxicity.

Dietary calcium is a type of calcium that is obtained through food sources. Calcium is an essential mineral that is necessary for many bodily functions, including bone formation and maintenance, muscle contraction, nerve impulse transmission, and blood clotting.

The recommended daily intake of dietary calcium varies depending on age, sex, and other factors. For example, the recommended daily intake for adults aged 19-50 is 1000 mg, while women over 50 and men over 70 require 1200 mg per day.

Good dietary sources of calcium include dairy products such as milk, cheese, and yogurt; leafy green vegetables like broccoli and kale; fortified cereals and juices; and certain types of fish, such as salmon and sardines. It is important to note that some foods can inhibit the absorption of calcium, including oxalates found in spinach and rhubarb, and phytates found in whole grains and legumes.

If a person is unable to get enough calcium through their diet, they may need to take calcium supplements. However, it is important to talk to a healthcare provider before starting any new supplement regimen, as excessive intake of calcium can lead to negative health effects.

Phosphates, in a medical context, refer to the salts or esters of phosphoric acid. Phosphates play crucial roles in various biological processes within the human body. They are essential components of bones and teeth, where they combine with calcium to form hydroxyapatite crystals. Phosphates also participate in energy transfer reactions as phosphate groups attached to adenosine diphosphate (ADP) and adenosine triphosphate (ATP). Additionally, they contribute to buffer systems that help maintain normal pH levels in the body.

Abnormal levels of phosphates in the blood can indicate certain medical conditions. High phosphate levels (hyperphosphatemia) may be associated with kidney dysfunction, hyperparathyroidism, or excessive intake of phosphate-containing products. Low phosphate levels (hypophosphatemia) might result from malnutrition, vitamin D deficiency, or certain diseases affecting the small intestine or kidneys. Both hypophosphatemia and hyperphosphatemia can have significant impacts on various organ systems and may require medical intervention.

Antidiuretic agents are medications or substances that reduce the amount of urine produced by the body. They do this by increasing the reabsorption of water in the kidneys, which leads to a decrease in the excretion of water and solutes in the urine. This can help to prevent dehydration and maintain fluid balance in the body.

The most commonly used antidiuretic agent is desmopressin, which works by mimicking the action of a natural hormone called vasopressin (also known as antidiuretic hormone or ADH). Vasopressin is produced by the pituitary gland and helps to regulate water balance in the body. When the body's fluid levels are low, vasopressin is released into the bloodstream, where it causes the kidneys to reabsorb more water and produce less urine.

Antidiuretic agents may be used to treat a variety of medical conditions, including diabetes insipidus (a rare disorder that causes excessive thirst and urination), bedwetting in children, and certain types of headaches. They may also be used to manage fluid balance in patients with kidney disease or heart failure.

It is important to use antidiuretic agents only under the supervision of a healthcare provider, as they can have side effects and may interact with other medications. Overuse or misuse of these drugs can lead to water retention, hyponatremia (low sodium levels in the blood), and other serious complications.

Magnesium is an essential mineral that plays a crucial role in various biological processes in the human body. It is the fourth most abundant cation in the body and is involved in over 300 enzymatic reactions, including protein synthesis, muscle and nerve function, blood glucose control, and blood pressure regulation. Magnesium also contributes to the structural development of bones and teeth.

In medical terms, magnesium deficiency can lead to several health issues, such as muscle cramps, weakness, heart arrhythmias, and seizures. On the other hand, excessive magnesium levels can cause symptoms like diarrhea, nausea, and muscle weakness. Magnesium supplements or magnesium-rich foods are often recommended to maintain optimal magnesium levels in the body.

Some common dietary sources of magnesium include leafy green vegetables, nuts, seeds, legumes, whole grains, and dairy products. Magnesium is also available in various forms as a dietary supplement, including magnesium oxide, magnesium citrate, magnesium chloride, and magnesium glycinate.

Transient receptor potential vanilloid (TRPV) cation channels are a subfamily of transient receptor potential (TRP) channels, which are non-selective cation channels that play important roles in various physiological processes such as nociception, thermosensation, and mechanosensation. TRPV channels are activated by a variety of stimuli including temperature, chemical ligands, and mechanical forces.

TRPV channels are composed of six transmembrane domains with intracellular N- and C-termini. The TRPV subfamily includes six members: TRPV1 to TRPV6. Among them, TRPV1 is also known as the vanilloid receptor 1 (VR1) and is activated by capsaicin, the active component of hot chili peppers, as well as noxious heat. TRPV2 is activated by noxious heat and mechanical stimuli, while TRPV3 and TRPV4 are activated by warm temperatures and various chemical ligands. TRPV5 and TRPV6 are primarily involved in calcium transport and are activated by low pH and divalent cations.

TRPV channels play important roles in pain sensation, neurogenic inflammation, and temperature perception. Dysfunction of these channels has been implicated in various pathological conditions such as chronic pain, inflammatory diseases, and cancer. Therefore, TRPV channels are considered promising targets for the development of novel therapeutics for these conditions.

Sodium-phosphate cotransporter proteins, type III (NPTIII), are a subfamily of sodium-dependent phosphate transporters that play a crucial role in the regulation of phosphate homeostasis within the body. They are located primarily in the proximal tubule cells of the kidney and facilitate the active transport of inorganic phosphate (Pi) from the lumen into the cell, coupled with the movement of sodium ions (Na+) in the same direction.

The type III sodium-phosphate cotransporters consist of two isoforms, NaPi-IIa and NaPi-IIc, which are encoded by the SLC34A1 and SLC34A3 genes, respectively. These proteins have a molecular weight of approximately 80-90 kDa and contain 13 transmembrane domains, with both the N- and C-termini located intracellularly.

NaPi-IIa is responsible for the majority of sodium-dependent phosphate reabsorption in the kidney, while NaPi-IIc plays a modulatory role under conditions of high dietary phosphate intake or during development. Dysregulation of these cotransporters has been implicated in various pathological conditions, such as chronic kidney disease (CKD), tumoral calcinosis, and certain forms of hypophosphatemic rickets.

In summary, sodium-phosphate cotransporter proteins, type III, are essential for maintaining phosphate balance by mediating the active reabsorption of inorganic phosphate from the kidney tubular lumen into the bloodstream.

Thiazides are a class of diuretic drugs that promote the excretion of salt and water from the body by inhibiting the reabsorption of sodium and chloride ions in the distal convoluted tubule of the nephron in the kidney. Chemically, thiazides contain a sulfonamide group and a benzothiadiazine ring.

Thiazide diuretics are widely used in the treatment of hypertension (high blood pressure), heart failure, and edema (fluid retention) associated with various medical conditions such as liver cirrhosis, kidney disease, and nephrotic syndrome. Examples of thiazide diuretics include hydrochlorothiazide, chlorthalidone, indapamide, and metolazone.

It is important to note that while thiazides are effective in reducing fluid volume and blood pressure, they can also cause electrolyte imbalances, including hypokalemia (low potassium levels), hyponatremia (low sodium levels), and hypercalcemia (high calcium levels). Therefore, patients taking thiazide diuretics should be monitored closely for any signs of electrolyte abnormalities.

I must clarify that the term "pedigree" is not typically used in medical definitions. Instead, it is often employed in genetics and breeding, where it refers to the recorded ancestry of an individual or a family, tracing the inheritance of specific traits or diseases. In human genetics, a pedigree can help illustrate the pattern of genetic inheritance in families over multiple generations. However, it is not a medical term with a specific clinical definition.

Hypocalcemia is a medical condition characterized by an abnormally low level of calcium in the blood. Calcium is a vital mineral that plays a crucial role in various bodily functions, including muscle contraction, nerve impulse transmission, and bone formation. Normal calcium levels in the blood usually range from 8.5 to 10.2 milligrams per deciliter (mg/dL). Hypocalcemia is typically defined as a serum calcium level below 8.5 mg/dL or, when adjusted for albumin (a protein that binds to calcium), below 8.4 mg/dL (ionized calcium).

Hypocalcemia can result from several factors, such as vitamin D deficiency, hypoparathyroidism (underactive parathyroid glands), kidney dysfunction, certain medications, and severe magnesium deficiency. Symptoms of hypocalcemia may include numbness or tingling in the fingers, toes, or lips; muscle cramps or spasms; seizures; and, in severe cases, cognitive impairment or cardiac arrhythmias. Treatment typically involves correcting the underlying cause and administering calcium and vitamin D supplements to restore normal calcium levels in the blood.

Kidney tubules are the structural and functional units of the kidney responsible for reabsorption, secretion, and excretion of various substances. They are part of the nephron, which is the basic unit of the kidney's filtration and reabsorption process.

There are three main types of kidney tubules:

1. Proximal tubule: This is the initial segment of the kidney tubule that receives the filtrate from the glomerulus. It is responsible for reabsorbing approximately 65% of the filtrate, including water, glucose, amino acids, and electrolytes.
2. Loop of Henle: This U-shaped segment of the tubule consists of a thin descending limb, a thin ascending limb, and a thick ascending limb. The loop of Henle helps to concentrate urine by creating an osmotic gradient that allows water to be reabsorbed in the collecting ducts.
3. Distal tubule: This is the final segment of the kidney tubule before it empties into the collecting duct. It is responsible for fine-tuning the concentration of electrolytes and pH balance in the urine by selectively reabsorbing or secreting substances such as sodium, potassium, chloride, and hydrogen ions.

Overall, kidney tubules play a critical role in maintaining fluid and electrolyte balance, regulating acid-base balance, and removing waste products from the body.

A kidney, in medical terms, is one of two bean-shaped organs located in the lower back region of the body. They are essential for maintaining homeostasis within the body by performing several crucial functions such as:

1. Regulation of water and electrolyte balance: Kidneys help regulate the amount of water and various electrolytes like sodium, potassium, and calcium in the bloodstream to maintain a stable internal environment.

2. Excretion of waste products: They filter waste products from the blood, including urea (a byproduct of protein metabolism), creatinine (a breakdown product of muscle tissue), and other harmful substances that result from normal cellular functions or external sources like medications and toxins.

3. Endocrine function: Kidneys produce several hormones with important roles in the body, such as erythropoietin (stimulates red blood cell production), renin (regulates blood pressure), and calcitriol (activated form of vitamin D that helps regulate calcium homeostasis).

4. pH balance regulation: Kidneys maintain the proper acid-base balance in the body by excreting either hydrogen ions or bicarbonate ions, depending on whether the blood is too acidic or too alkaline.

5. Blood pressure control: The kidneys play a significant role in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), which constricts blood vessels and promotes sodium and water retention to increase blood volume and, consequently, blood pressure.

Anatomically, each kidney is approximately 10-12 cm long, 5-7 cm wide, and 3 cm thick, with a weight of about 120-170 grams. They are surrounded by a protective layer of fat and connected to the urinary system through the renal pelvis, ureters, bladder, and urethra.

Creatinine is a waste product that's produced by your muscles and removed from your body by your kidneys. Creatinine is a breakdown product of creatine, a compound found in meat and fish, as well as in the muscles of vertebrates, including humans.

In healthy individuals, the kidneys filter out most of the creatinine and eliminate it through urine. However, when the kidneys are not functioning properly, creatinine levels in the blood can rise. Therefore, measuring the amount of creatinine in the blood or urine is a common way to test how well the kidneys are working. High creatinine levels in the blood may indicate kidney damage or kidney disease.

Citric acid is a weak organic acid that is widely found in nature, particularly in citrus fruits such as lemons and oranges. Its chemical formula is C6H8O7, and it exists in a form known as a tribasic acid, which means it can donate three protons in chemical reactions.

In the context of medical definitions, citric acid may be mentioned in relation to various physiological processes, such as its role in the Krebs cycle (also known as the citric acid cycle), which is a key metabolic pathway involved in energy production within cells. Additionally, citric acid may be used in certain medical treatments or therapies, such as in the form of citrate salts to help prevent the formation of kidney stones. It may also be used as a flavoring agent or preservative in various pharmaceutical preparations.

Sodium chloride symporter inhibitors are a class of pharmaceutical agents that block the function of the sodium chloride symporter (NCC), which is a protein found in the kidney's distal convoluted tubule. The NCC is responsible for reabsorbing sodium and chloride ions from the filtrate back into the bloodstream, helping to regulate electrolyte balance and blood pressure.

Sodium chloride symporter inhibitors work by selectively binding to and blocking the NCC, preventing it from transporting sodium and chloride ions across the cell membrane. This leads to increased excretion of sodium and chloride in the urine, which can help lower blood pressure in patients with hypertension.

Examples of sodium chloride symporter inhibitors include thiazide diuretics such as hydrochlorothiazide and chlorthalidone, which have been used for many years to treat hypertension and edema associated with heart failure and liver cirrhosis. These medications work by reducing the amount of sodium and fluid in the body, which helps lower blood pressure and reduce swelling.

It's worth noting that while sodium chloride symporter inhibitors can be effective at treating hypertension, they can also cause side effects such as electrolyte imbalances, dehydration, and increased urination. As with any medication, it's important to use them under the guidance of a healthcare provider and to follow dosing instructions carefully.

Urinalysis is a medical examination and analysis of urine. It's used to detect and manage a wide range of disorders, such as diabetes, kidney disease, and liver problems. A urinalysis can also help monitor medications and drug compliance. The test typically involves checking the color, clarity, and specific gravity (concentration) of urine. It may also include chemical analysis to detect substances like glucose, protein, blood, and white blood cells, which could indicate various medical conditions. In some cases, a microscopic examination is performed to identify any abnormal cells, casts, or crystals present in the urine.

Hyperparathyroidism is a condition in which the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). There are four small parathyroid glands located in the neck, near or within the thyroid gland. They release PTH into the bloodstream to help regulate the levels of calcium and phosphorus in the body.

In hyperparathyroidism, overproduction of PTH can lead to an imbalance in these minerals, causing high blood calcium levels (hypercalcemia) and low phosphate levels (hypophosphatemia). This can result in various symptoms such as fatigue, weakness, bone pain, kidney stones, and cognitive issues.

There are two types of hyperparathyroidism: primary and secondary. Primary hyperparathyroidism occurs when there is a problem with one or more of the parathyroid glands, causing them to become overactive and produce too much PTH. Secondary hyperparathyroidism develops as a response to low calcium levels in the body due to conditions like vitamin D deficiency, chronic kidney disease, or malabsorption syndromes.

Treatment for hyperparathyroidism depends on the underlying cause and severity of symptoms. In primary hyperparathyroidism, surgery to remove the overactive parathyroid gland(s) is often recommended. For secondary hyperparathyroidism, treating the underlying condition and managing calcium levels with medications or dietary changes may be sufficient.

Uric acid is a chemical compound that is formed when the body breaks down purines, which are substances that are found naturally in certain foods such as steak, organ meats and seafood, as well as in our own cells. After purines are broken down, they turn into uric acid and then get excreted from the body in the urine.

However, if there is too much uric acid in the body, it can lead to a condition called hyperuricemia. High levels of uric acid can cause gout, which is a type of arthritis that causes painful swelling and inflammation in the joints, especially in the big toe. Uric acid can also form crystals that can collect in the kidneys and lead to kidney stones.

It's important for individuals with gout or recurrent kidney stones to monitor their uric acid levels and follow a treatment plan prescribed by their healthcare provider, which may include medications to lower uric acid levels and dietary modifications.

Hydrochlorothiazide is a diuretic drug, which means it helps the body get rid of extra salt and water by increasing the amount of urine that is produced. The medical definition of Hydrochlorothiazide is:

A thiazide diuretic drug used to treat hypertension and edema associated with heart failure, liver cirrhosis, and kidney disorders. It works by inhibiting the reabsorption of sodium and chloride ions in the distal convoluted tubule of the nephron, which increases water excretion and decreases blood volume and pressure. Hydrochlorothiazide may be used alone or in combination with other antihypertensive agents. It is also used to treat conditions such as diabetes insipidus, renal tubular acidosis, and hypercalcemia.

The usual starting dose of hydrochlorothiazide for adults is 25 mg to 50 mg once a day, which may be increased gradually depending on the patient's response. The maximum recommended daily dose is 100 mg. Common side effects of hydrochlorothiazide include increased urination, headache, dizziness, and muscle cramps.

Chloride channels are membrane proteins that form hydrophilic pores or gaps, allowing the selective passage of chloride ions (Cl-) across the lipid bilayer of cell membranes. They play crucial roles in various physiological processes, including regulation of neuronal excitability, maintenance of resting membrane potential, fluid and electrolyte transport, and pH and volume regulation of cells.

Chloride channels can be categorized into several groups based on their structure, function, and mechanism of activation. Some of the major classes include:

1. Voltage-gated chloride channels (ClC): These channels are activated by changes in membrane potential and have a variety of functions, such as regulating neuronal excitability and transepithelial transport.
2. Ligand-gated chloride channels: These channels are activated by the binding of specific ligands or messenger molecules, like GABA (gamma-aminobutyric acid) or glycine, and are involved in neurotransmission and neuromodulation.
3. Cystic fibrosis transmembrane conductance regulator (CFTR): This is a chloride channel primarily located in the apical membrane of epithelial cells, responsible for secreting chloride ions and water to maintain proper hydration and mucociliary clearance in various organs, including the lungs and pancreas.
4. Calcium-activated chloride channels (CaCCs): These channels are activated by increased intracellular calcium concentrations and participate in various physiological processes, such as smooth muscle contraction, neurotransmitter release, and cell volume regulation.
5. Swelling-activated chloride channels (ClSwells): Also known as volume-regulated anion channels (VRACs), these channels are activated by cell swelling or osmotic stress and help regulate cell volume and ionic homeostasis.

Dysfunction of chloride channels has been implicated in various human diseases, such as cystic fibrosis, myotonia congenita, epilepsy, and certain forms of cancer.

Parathyroid diseases refer to conditions that affect the parathyroid glands, which are small endocrine glands located in the neck, near or attached to the back surface of the thyroid gland. The primary function of the parathyroid glands is to produce and secrete parathyroid hormone (PTH), a crucial hormone that helps regulate calcium and phosphorus levels in the blood and bones.

There are four parathyroid glands, and they can develop various diseases, including:

1. Hyperparathyroidism: A condition where one or more parathyroid glands produce excessive amounts of PTH. This can lead to an imbalance in calcium and phosphorus levels, resulting in symptoms such as fatigue, weakness, bone pain, kidney stones, and increased risk of osteoporosis. Hyperparathyroidism can be primary (caused by a benign or malignant tumor in the parathyroid gland), secondary (due to chronic kidney disease or vitamin D deficiency), or tertiary (when secondary hyperparathyroidism becomes autonomous and continues even after correcting the underlying cause).
2. Hypoparathyroidism: A condition where the parathyroid glands do not produce enough PTH, leading to low calcium levels in the blood (hypocalcemia) and high phosphorus levels (hyperphosphatemia). Symptoms of hypoparathyroidism may include muscle spasms, tingling sensations in the fingers, toes, or lips, anxiety, cataracts, and seizures. Hypoparathyroidism can be caused by surgical removal of the parathyroid glands, autoimmune disorders, radiation therapy, or genetic conditions.
3. Parathyroid tumors: Abnormal growths in the parathyroid glands can lead to hyperparathyroidism. Benign tumors (adenomas) are the most common cause of primary hyperparathyroidism. Malignant tumors (carcinomas) are rare but can also occur, leading to more severe symptoms and a worse prognosis.
4. Parathyroid dysfunction in genetic disorders: Some genetic syndromes, such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), and hyperparathyroidism-jaw tumor syndrome (HPT-JT), can involve parathyroid gland abnormalities, leading to hyperparathyroidism or other related conditions.

Proper diagnosis and management of parathyroid disorders are crucial for maintaining optimal calcium homeostasis and preventing complications associated with hypocalcemia or hypercalcemia. Treatment options may include surgery, medication, dietary modifications, and monitoring hormone levels.

Vesico-Ureteral Reflux (VUR) is a medical condition that affects the urinary system, specifically the junction where the ureters (tubes that carry urine from the kidneys to the bladder) connect with the bladder. In normal physiology, once the bladder fills up with urine and contracts during micturition (urination), the pressure within the bladder should prevent the backflow of urine into the ureters.

However, in VUR, the valve-like mechanism that prevents this backflow does not function properly, allowing urine to flow backward from the bladder into the ureters and potentially even into the kidneys. This reflux can lead to recurrent urinary tract infections (UTIs), kidney damage, and other complications if left untreated. VUR is more commonly diagnosed in children but can also occur in adults.

Sodium-phosphate cotransporter proteins are membrane transport proteins that facilitate the active transport of sodium and inorganic phosphate ions across biological membranes. These proteins play a crucial role in maintaining phosphate homeostasis within the body by regulating the absorption and excretion of phosphate in the kidneys and intestines. They exist in two major types, type I (NaPi-I) and type II (NaPi-II), each having multiple subtypes with distinct tissue distributions and regulatory mechanisms.

Type I sodium-phosphate cotransporters are primarily expressed in the kidney's proximal tubules and play a significant role in reabsorbing phosphate from the primary urine back into the bloodstream. Type II sodium-phosphate cotransporters, on the other hand, are found in both the kidneys and intestines. In the kidneys, they contribute to phosphate reabsorption, while in the intestines, they facilitate phosphate absorption from food.

These proteins function by coupling the passive downhill movement of sodium ions (driven by the electrochemical gradient) with the active uphill transport of phosphate ions against their concentration gradient. This coupled transport process enables cells to maintain intracellular phosphate concentrations within a narrow range, despite fluctuations in dietary intake and renal function.

Dysregulation of sodium-phosphate cotransporter proteins has been implicated in various pathological conditions, such as chronic kidney disease (CKD), tumoral calcinosis, and certain genetic disorders affecting phosphate homeostasis.

Metabolic bone diseases are a group of conditions that affect the bones and are caused by disorders in the body's metabolism. These disorders can result in changes to the bone structure, density, and strength, leading to an increased risk of fractures and other complications. Some common examples of metabolic bone diseases include:

1. Osteoporosis: a condition characterized by weak and brittle bones that are more likely to break, often as a result of age-related bone loss or hormonal changes.
2. Paget's disease of bone: a chronic disorder that causes abnormal bone growth and deformities, leading to fragile and enlarged bones.
3. Osteomalacia: a condition caused by a lack of vitamin D or problems with the body's ability to absorb it, resulting in weak and soft bones.
4. Hyperparathyroidism: a hormonal disorder that causes too much parathyroid hormone to be produced, leading to bone loss and other complications.
5. Hypoparathyroidism: a hormonal disorder that results in low levels of parathyroid hormone, causing weak and brittle bones.
6. Renal osteodystrophy: a group of bone disorders that occur as a result of chronic kidney disease, including osteomalacia, osteoporosis, and high turnover bone disease.

Treatment for metabolic bone diseases may include medications to improve bone density and strength, dietary changes, exercise, and lifestyle modifications. In some cases, surgery may be necessary to correct bone deformities or fractures.

The parathyroid glands are four small endocrine glands located in the neck, usually near or behind the thyroid gland. They secrete parathyroid hormone (PTH), which plays a critical role in regulating calcium and phosphate levels in the blood and bones. PTH helps maintain the balance of these minerals by increasing the absorption of calcium from food in the intestines, promoting reabsorption of calcium in the kidneys, and stimulating the release of calcium from bones when needed. Additionally, PTH decreases the excretion of calcium through urine and reduces phosphate reabsorption in the kidneys, leading to increased phosphate excretion. Disorders of the parathyroid glands can result in conditions such as hyperparathyroidism (overactive glands) or hypoparathyroidism (underactive glands), which can have significant impacts on calcium and phosphate homeostasis and overall health.

Distal kidney tubules are the final segment of the renal tubule in the nephron of the kidney. The nephron is the basic unit of the kidney that filters blood and produces urine. After the filtrate leaves the glomerulus, it enters the proximal tubule where most of the reabsorption of water, electrolytes, and nutrients occurs.

The filtrate then moves into the loop of Henle, which is divided into a thin and thick descending limb and a thin and thick ascending limb. The loop of Henle helps to establish a concentration gradient in the medullary interstitium, allowing for the reabsorption of water in the collecting ducts.

The distal tubule is the last segment of the renal tubule before the filtrate enters the collecting duct. It is a relatively short structure that receives filtrate from the thick ascending limb of the loop of Henle. The distal tubule plays an important role in regulating electrolyte and water balance by actively transporting ions such as sodium, potassium, and chloride.

The distal tubule also contains specialized cells called principal cells and intercalated cells that are responsible for secreting or reabsorbing hydrogen and potassium ions to maintain acid-base balance. Additionally, the distal tubule is a site of action for several hormones, including aldosterone, which stimulates sodium reabsorption and potassium excretion, and vasopressin (antidiuretic hormone), which promotes water reabsorption in the collecting ducts.

Hematuria is a medical term that refers to the presence of blood in urine. It can be visible to the naked eye, which is called gross hematuria, or detected only under a microscope, known as microscopic hematuria. The blood in urine may come from any site along the urinary tract, including the kidneys, ureters, bladder, or urethra. Hematuria can be a symptom of various medical conditions, such as urinary tract infections, kidney stones, kidney disease, or cancer of the urinary tract. It is essential to consult a healthcare professional if you notice blood in your urine to determine the underlying cause and receive appropriate treatment.

Intestinal absorption refers to the process by which the small intestine absorbs water, nutrients, and electrolytes from food into the bloodstream. This is a critical part of the digestive process, allowing the body to utilize the nutrients it needs and eliminate waste products. The inner wall of the small intestine contains tiny finger-like projections called villi, which increase the surface area for absorption. Nutrients are absorbed into the bloodstream through the walls of the capillaries in these villi, and then transported to other parts of the body for use or storage.

A nephron is the basic structural and functional unit of the kidney. It is responsible for filtering blood, reabsorbing necessary substances, and excreting waste products into the urine. Each human kidney contains approximately one million nephrons.

The structure of a nephron includes a glomerulus, which is a tuft of capillaries surrounded by Bowman's capsule. The glomerulus filters blood, allowing small molecules like water and solutes to pass through while keeping larger molecules like proteins and blood cells within the capillaries.

The filtrate then passes through the tubular portion of the nephron, which includes the proximal convoluted tubule, loop of Henle, distal convoluted tubule, and collecting duct. The tubular portion reabsorbs necessary substances like water, glucose, amino acids, and electrolytes back into the bloodstream while excreting waste products like urea and creatinine into the urine.

Overall, nephrons play a critical role in maintaining fluid and electrolyte balance, regulating blood pressure, and removing waste products from the body.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

Bone resorption is the process by which bone tissue is broken down and absorbed into the body. It is a normal part of bone remodeling, in which old or damaged bone tissue is removed and new tissue is formed. However, excessive bone resorption can lead to conditions such as osteoporosis, in which bones become weak and fragile due to a loss of density. This process is carried out by cells called osteoclasts, which break down the bone tissue and release minerals such as calcium into the bloodstream.

Hypercalciuria is the condition of elevated calcium in the urine. Chronic hypercalciuria may lead to impairment of renal ... Hypercalciuria in patients can be due to underlying genetic causes. Signs and symptoms There are no clinical signs or symptoms ... Patients with hypercalciuria have kidneys that excrete higher levels of calcium than normal, for which there are many possible ... Additionally, hypercalciuria can contribute to kidney stone formation which may present with flank or back pain that comes and ...
... and at least one third of all calcium stone formers are found to have hypercalciuria when tested. ... Hypercalciuria, or excessive urinary calcium excretion, occurs in about 5-10% of the population and is the most common ... Renal leak hypercalciuria. Renal leak hypercalciuria occurs in about 5-10% of calcium-stone formers and is characterized by ... Absorptive hypercalciuria. Absorptive hypercalciuria is by far the most common cause of excessive urinary calcium. About 50% of ...
"Hypercalciuria" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Hypercalciuria" by people in this website by year, and whether ... Below are the most recent publications written about "Hypercalciuria" by people in Profiles. ... "Hypercalciuria" was a major or minor topic of these publications. To see the data from this visualization as text, click here. ...
Hypercalciuria (2) Hyperoxaluria (2) Hyperuricoscuria (2) Hypocitraturia (2) ICD-10 (49) ICD-10 Codes (7) Kidney (2) Knee Pain ...
Treatment currently focuses on reducing stone risk through treatment of hypercalciuria with sodium restriction and thiazide ...
Hypercalciuria-High Calcium in Urine. Posted on September 28, 2010. September 10, 2013. ... In general, the most frequent cause of calcium kidney stones is hypercalciuria (an excessive amount of calcium in the urine). ...
Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH). what is hereditary hypophosphatemic rickets with hypercalciuria ... Mild forms may present with hypercalciuria and nephrolithiasis without the bone disease. They are more prone to develop ... What are the symptoms and signs of hereditary hypophosphatemic rickets with hypercalciuria (HHRH)?. ... What are the biochemical findings of hereditary hypophosphatemic rickets with hypercalciuria (HHRH)?. ...
Forty-nine had idiopathic hypercalciuria, defined by a urine calcium greater than 7 mmol/day on a free diet. Twenty-two were ... Forty-nine had idiopathic hypercalciuria, defined by a urine calcium greater than 7 mmol/day on a free diet. Twenty-two were ... Forty-nine had idiopathic hypercalciuria, defined by a urine calcium greater than 7 mmol/day on a free diet. Twenty-two were ... Forty-nine had idiopathic hypercalciuria, defined by a urine calcium greater than 7 mmol/day on a free diet. Twenty-two were ...
... hypercalciuria of renal origin) should be excluded. Patients with normal calcium levels and elevated parathyroid hormone levels ...
Management of hypercalciuria (?250 mg/d) to reduce stone risk may require dietary and/or medical therapy. Dietary advice is ... Our results reveal that one-third of patients with hypercalciuria exceeded the RDA for calcium intake, and less than half had ... Does Dietary Assessment Aid in Decision-Making for Medical Management of Hypercalciuria?. View Poster ... MP31-14: Does Dietary Assessment Aid in Decision-Making for Medical Management of Hypercalciuria?. ...
Patients with medullary sponge kidney who demonstrate risk factors for stone formation (ie, hypocitraturia, hypercalciuria, ... Patients with medullary sponge kidney who demonstrate risk factors for stone formation (ie, hypocitraturia, hypercalciuria, ... Its use is indicated in patients with medullary sponge kidney with hypercalciuria. ... and aggressive diuresis may be helpful in patients with medullary sponge kidney and hypercalciuria. ...
... for hypercalciuria. The contribution of polygenic influences from multiple loci have been investigated by genome-wide ... is a common problem that can be associated with alterations in urinary solute composition including hypercalciuria. Studies ... Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5. PLoS One 8, ... A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335 ...
Renal hypercalciuria - one of the most important secondary causes of osteoporosis; can be treated with thiazide diuretics ...
About half of people who develop calcium stones have high levels of calcium in the urine (hypercalciuria). Hypercalciuria often ... Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016 Sep;12(9):519-33. doi: 10.1038/nrneph. ...
Leslie SW, Sajjad H. Hypercalciuria. 2019 Sep 28. StatPearls [Internet].Treasure Island (FL): StatPearls Publishing; 2019 Jan ... Hypercalciuria. Textbook Chapter: Emedicine/Medscape Reference. Available at: http://emedicine.medscape.com/article/2182757- ...
Three patients had massive hypercalciuria (calcium/creatinine ratio 1.8-4.8 mol/mol, normal less than 1). The 25 (OH) vitamin ... Vitamin D poisoning in infants: a preventable cause of hypercalciuria and nephrocalcinosis]. / Vitamin-D-Intoxikation beim ... Vitamin D intoxication still has to be considered as a possible cause of hypercalciuria. ... Vitamin D poisoning in infants: a preventable cause of hypercalciuria and nephrocalcinosi ...
Prevention of recurrent stones in idiopathic hypercalciuria. Bataille P, Presne C, Fournier A. Bataille P, et al. N Engl J Med ... Prevention of recurrent stones in idiopathic hypercalciuria. Teichman J. Teichman J. N Engl J Med. 2002 May 23;346(21):1667-9. ...
Keiko I. Greenberg,MD, specializes in Nephrology and is on staff at MedStar Georgetown University Hospital. Click here for more information and to make an appointment.
Urinary calcium measurement is used in the differential diagnosis of hypercalciuria.. Total Protein ...
Hypercalciuria. hyperparathyroidism p. 344. Hyperparathyroidism p. 344. associations p. 729. calcium pyrophosphate deposition ...
Hypercalciuria QTL 2. 2.15. urine calcium amount (VT:0002985). urine calcium excretion rate (CMO:0000763). 4. 210796. 45210796 ...
Hypocalcemia is a state of electrolyte imbalance in which the circulating serum calcium level is low. During hypocalcemia, the total calcium level and the ionized calcium level fall below the laboratory reference range. Hypocalcemia may occur subsequent to failure of any of the mechanisms by whic...
J Urol 1994 Oct;152(4):1226-8. Urinary incontinence due to idiopathic hypercalciuria in children. Vachvanichsanong P, Malagon M ... Prolonged dietary calcium restriction: a diagnostic approach in idiopathic Hypercalciuria. Muller D, Eggert P. ... Clin Nephrol 2002 Mar;57(3):183-91.. Bone involvement in idiopathic hypercalciuria. Misael da Silva AM, dos Reis LM, Pereira RC ... Chronic metabolic acidosis typically results in hypercalciuria and negative calcium balance. The impact of chronic respiratory ...
Sunlight and hypercalciuria. Lancet, 1975, 1(7915):1063-5.. *Robertson WG, Peacock M, Heyburn PJ. The risk of calcium stone ...
Prolonged dietary calcium restriction: a diagnostic approach in idiopathic hypercalciuria Nephron Return to Home Page ...
Gigantism refers to abnormally high linear growth due to excessive action of insulinlike growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood.
GI discomfort, hypercalcemia, hypercalciuria. Caltrate 600 + D Clinical Trials. See Literature. Caltrate 600 + D Note. Not ...
Hypercalciuria Need a Curbside Consult? Share cases and questions with Physicians on Medscape consult. Share a Case ...
Most common adverse reactions (incidence ≥ 3%) are hypercalcemia, hypercalciuria, and skin discomfort. (6.1). ... hypercalciuria (3%), and discomfort of skin (3%). Kidney stones were reported in 3 subjects and confirmed in two.. ...

No FAQ available that match "hypercalciuria"

No images available that match "hypercalciuria"